Israel Active

Neural growth factor proteins can limit damage from Alzheimer’s disease but are normally blocked by the Blood Brain Barrier. Scientists at Israel’s Technion Institute and Bar-Ilan University have developed nanoscale silicon chips that deliver these proteins directly to the target brain tissue.

Good results of the first multi-center human trials of the Alpha Dart radiation therapy developed by Israel’s Alpha Tau. Over 78% of the skin cancer tumors were completely cured. Most of the patients had previously received other treatments that failed to kill the tumors.

Israeli startup Pepticom uses AI (Artificial Intelligence) to discover new peptide-based candidates that could become the basis of the next big medical treatment. Pepticom was launched as a company by Yissum – the technology transfer arm of the Hebrew University of Jerusalem.

Israel’s Fidmi has received FDA approval for its low profile gastronomy system / enteral feeding device . Its easily replaceable inner tube which can be changed by patients without the need to visit a doctor or nurse.

As reported previously, the Virtual Reality technology from Israel’s Surgical Theater is saving thousands of lives. Here is one example of two-year-old Ari whose deep brain tumor was removed, thanks to surgeons having practiced the delicate operation using the groundbreaking VR system.

Israel’s Perflow Medical has received the CE Mark (European approval) for its Cascade Agile device that helps surgeons repair ruptured intercranial aneurysms. Its unique net design enables continuous blood flow during cerebral aneurysm operations.

Since US giant Medtronic began marketing the AI brain scan analysis system from Israel’s Viz.ai , it has been installed in 300 US hospitals. Viz.ai has just raised $50 million to help fund its fast growth.

Israel’s MedHub is developing AutocathFFR - an automated system that detects stenoses (narrowing) in the coronary arteries surrounding the heart. It has just commenced a pivotal multi-center clinical trial to test the system’s effectiveness.

As reported previously, Israel’s Biomica is developing microbiome therapies for antibiotic resistant bacteria. It is now partnering with the Weizmann Institute to develop a selective treatment against MRSA - antibiotic resistant strains of Staphylococcus aureus infection.

Israeli doctors performed the first commercial replacement surgery of the meniscus (knee cartilage) on two Israeli patients. Via a small incision, they each received the NUsurface artificial meniscus implant developed at the Netanya, Israel R&D center of US company Active Implants.